Today’s AI Top Pick: TEM

7/23/2026 · Model-Backed Squeeze screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · TEM70%218 resolved forecasts · 45d window · verify →

View the live TEM price forecast →

Today's pick · Model-Backed SqueezeTEMBUY NOW7.6 / 107/23/2026

TEM is the only name in the pool and it passes the screen convincingly with a compelling multi-timeframe setup. The daily and weekly forecast tapes are strongly bullish: 1d fc_mid_pct of +41.8% and fc_long_pct of +31.3%, with the 1wk fc_mid_pct at +40.3% and fc_long_pct at +32.9%. Near-term is also constructive — 1d fc_short_pct of +10.96% and 1wk fc_short_pct of +15.14% — while the 1h/4h short-term forecasts are only marginally negative (-0.41% / -0.37%), suggesting the model sees a brief basing period before the larger move. Bullish probability is 1.0 across the board. Crucially, this is NOT a chase. Position in the 21-bar range is 3.01% on the daily and 3.76% on the 4h, with drawdowns of -23.05% (1d) and -19.18% (4h) from local highs. You are buying near the low of the recent range, not extending. RSI at 38.16 confirms the oversold-but-not-broken tape. The screen criteria (short float 31.67%, well above the 15% floor) sets up genuine squeeze fuel if the forecasted rebound materializes, and analyst targetUpsidePct of +41.8% independently corroborates the model's mid-term view. Fundamentals are mixed but explainable for a high-growth AI healthcare name: sales YoY +69.82%, gross margin 62.22%, and next-year EPS growth of +87.67% offset the -22.2% profit margin and -81.58% ROE. Debt/equity of 3.17 and operating margin -18.75% are real risks, hence the fundamental_score of -1, but the growth trajectory and analyst recom of 2.16 (buy-leaning) support the thesis. Today's headlines are a positive catalyst stack, not a landmine: Tempus's $1.5B bet to corner the cancer-test market (Personalis deal) and the OneOme pharmacogenomics launch are both expansion-of-TAM stories, not dilution or guidance-cut red flags. Why today: price is pinned near the bottom of the 21-bar range on multiple timeframes right after a fresh strategic catalyst, with a 31.67% short float and a model forecasting +40%+ over the mid horizon. Waiting risks missing the reflex bounce off oversold; the setup rewards adding here with a tight invalidation just under the 4h low.

TEM forecast chart
Entry zone
$46.50 - $47.80 (buy at/near current $47.40, add on dips toward $46.50)
Stop loss
$42.90 (below the 4h 21-bar low, ~9.5% risk)
First target
$52.50 - $54.00 (reclaim mid-range, ~10-14% consistent with 1d fc_short of +10.96%)
Longer target
$63 - $67 (aligned with 1d/1wk fc_mid of +40%+ and analyst targetUpsidePct of +41.8%)
Risks
  • Profit margin -22.2% and ROE -81.58% — TEM is unprofitable; any risk-off tape punishes cash-burning growth names hardest
  • Debt/Equity of 3.17 is elevated; the $1.5B Personalis acquisition raises integration and potential dilution/financing risk
  • Short float of 31.67% cuts both ways — can squeeze up, but also signals real skepticism; -23.05% drawdown on the daily shows sellers are still in control near term
  • Short-term 1h/4h forecasts are slightly negative (-0.41% / -0.37%), so near-term chop is likely before the mid-horizon move materializes
  • Position in 21-bar range at 3.01% (1d) means there's no clear technical support directly below current price — a break of $46 could air-pocket to $43
Full ranking (1)
#SymbolVerdictScoreRead
1TEMBUY NOW7.6Oversold high-short-interest AI healthcare name with +40% mid-horizon model forecast, fresh $1.5B strategic catalyst, and price pinned at 3% of 21-bar range.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.